ロード中...
FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma
On August 16, 2018, the U.S. Food and Drug Administration approved lenvatinib (Lenvima, Eisai Inc.) for first‐line treatment of patients with unresectable hepatocellular carcinoma (HCC). Approval was based on an international, multicenter, randomized, open‐label, noninferiority trial (REFLECT; NCT01...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7930400/ https://ncbi.nlm.nih.gov/pubmed/33044793 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13566 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|